{"id":52295,"date":"2022-12-22T17:02:15","date_gmt":"2022-12-22T16:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-neuromodulation-devices-market-analysis-report-2022-an-8-3-billion-market-by-2030-focus-on-spinal-cord-stimulators-deep-brain-stimulators-researchandmarkets-com\/"},"modified":"2022-12-22T17:02:15","modified_gmt":"2022-12-22T16:02:15","slug":"global-neuromodulation-devices-market-analysis-report-2022-an-8-3-billion-market-by-2030-focus-on-spinal-cord-stimulators-deep-brain-stimulators-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-neuromodulation-devices-market-analysis-report-2022-an-8-3-billion-market-by-2030-focus-on-spinal-cord-stimulators-deep-brain-stimulators-researchandmarkets-com\/","title":{"rendered":"Global Neuromodulation Devices Market Analysis Report 2022: An $8.3 Billion Market by 2030 – Focus on Spinal Cord Stimulators & Deep Brain Stimulators – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Neuromodulation Devices Market Size, Share & Trends Analysis Report by Product Type (Spinal Cord Stimulators, Deep Brain Stimulators), by Technology, by Application, by Biomaterial, by End-use, by Region, and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global neuromodulation devices market size is expected to reach USD 8.3 billion by 2030 and is expected to expand at a CAGR of 9.5% from 2022 to 2030\n<\/p>\n

\nNeuromodulation offers minimally invasive or non-invasive treatment options for the treatment of neurological diseases. In addition, the growth in the healthcare budgetary allocation in developing countries is expected to contribute to the market growth. For instance, in the U.S., national healthcare spending increased to USD 4.1 trillion in 2020, or USD 12,530 per person.\n<\/p>\n

\nThe COVID-19 pandemic had caused havoc in a variety of industries and trades around the world. The demand for neuromodulation is higher among the older population as they are more likely to be exposed to chronic pain due to various comorbidities and probable immune suppression.\n<\/p>\n

\nFurthermore, the demand is expected to increase among persons infected with the COVID-19 virus. The illness effectively suppresses the immune system.\n<\/p>\n

\nThe significant increase in investments by the government and market players to improve the healthcare infrastructure is promoting the implementation of novel technologies to treat neurological conditions. In the Union Budget of 2021, the PM Atmanirbhar Swasth Bharat Yojana received funding from the government of India totaling USD 8.10 billion over six years.\n<\/p>\n

\nThe fund was allocated to strengthen existing national medical institutions to develop capacities of primary, secondary, and tertiary healthcare systems and cater to the detection of emerging diseases.\n<\/p>\n

\nMajor players operating in the market are receiving FDA approval for their products. The organizations are incorporating strategies such as alliances, acquisitions, partnerships, R&D investments, new product launches, and approvals to strengthen their competitive power while expanding their global reach.\n<\/p>\n

\nFor instance, in September 2021, Abbott acquired Walk Vascular, LLC, which is a medical device manufacturing company. Walk Vascular, LLC is known for the minimally invasive thrombectomy system that is designed for the removal of blood clots.\n<\/p>\n

\nNeuromodulation Devices Market Report Highlights<\/strong>\n<\/p>\n